| John P Maclaurin, DO | |
|
285 E State St, Suite 150, Columbus, OH 43215-4354 | |
| (614) 460-6100 | |
| Not Available |
| Full Name | John P Maclaurin |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Nephrology |
| Location | 285 E State St, Columbus, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184672438 | NPI | - | NPPES |
| 0342669 | Medicaid | OH | |
| 110029320 | Other | OH | MEDICARE RAILROAD |
| 000000119403 | Other | ANTHEM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 34002174 (Ohio) | Primary |
| Entity Name | Hypertension Nephrology Consultants Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477501591 PECOS PAC ID: 6901796366 Enrollment ID: O20040318000798 |
News Archive
Women at high-risk of cardiovascular disease who took a daily supplement of folic acid and vitamin B6 and B12 for seven years did not have an overall reduced rate of cardiovascular events, despite a significant lowering of homocysteine levels, according to a study in the May 7 issue of JAMA, the Journal of the American Medical Association.
Pain Therapeutics, Inc. announced today that it has been awarded over $2,000,000 in research grants by the U.S. government. These grants are planned to support the Company's on-going biomedical research for nervous system disorders and oncology. Pain Therapeutics expects to receive funding from these research grants now through the end of 2011.
Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.
Nearly 90 percent of medical journals with relatively high impact factors have policies addressing author conflict of interest (COI) available for public review, according to a report in the November 25 issue of JAMA. But many journals do not require authors to sign disclosure statements, and there is variability in how COI is defined.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John P Maclaurin, DO Po Box 182255, Columbus, OH 43218-2255 Ph: (614) 430-5712 | John P Maclaurin, DO 285 E State St, Suite 150, Columbus, OH 43215-4354 Ph: (614) 460-6100 |
News Archive
Women at high-risk of cardiovascular disease who took a daily supplement of folic acid and vitamin B6 and B12 for seven years did not have an overall reduced rate of cardiovascular events, despite a significant lowering of homocysteine levels, according to a study in the May 7 issue of JAMA, the Journal of the American Medical Association.
Pain Therapeutics, Inc. announced today that it has been awarded over $2,000,000 in research grants by the U.S. government. These grants are planned to support the Company's on-going biomedical research for nervous system disorders and oncology. Pain Therapeutics expects to receive funding from these research grants now through the end of 2011.
Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.
Nearly 90 percent of medical journals with relatively high impact factors have policies addressing author conflict of interest (COI) available for public review, according to a report in the November 25 issue of JAMA. But many journals do not require authors to sign disclosure statements, and there is variability in how COI is defined.
› Verified 5 days ago
Sethu M. Madhavan, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 300 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3387 Fax: 614-366-0073 | |
Amrik Singh Khalsa, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 700 Childrens Dr, Columbus, OH 43205 Phone: 614-722-2000 Fax: 614-722-4966 | |
Samuel Y. Han, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-6255 Fax: 614-293-1456 | |
Dr. Ruchi Bhatia, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3400 Olentangy River Rd, Columbus, OH 43202 Phone: 614-754-5500 Fax: 614-457-9519 | |
Adam T. Ramey, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-7499 Fax: 614-366-2360 | |
Albert J. Cook, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-2957 Fax: 614-685-6533 | |
Walter G. Hanel Iv, MD, PHD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3196 Fax: 614-293-4812 |